Detalles de la búsqueda
1.
Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Am J Hematol
; 95(9): 1038-1046, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32438452
2.
A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
Blood Cells Mol Dis
; 68: 185-191, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28126395
3.
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Blood Cells Mol Dis
; 77: 101-102, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31029022
4.
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Blood Cells Mol Dis
; 71: 71-74, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29680197
5.
Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Orphanet J Rare Dis
; 14(1): 128, 2019 06 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31174576
6.
Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Mol Genet Metab Rep
; 8: 17-9, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27408819
7.
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Mol Genet Metab Rep
; 9: 25-28, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27722092
Resultados
1 -
7
de 7
1
Próxima >
>>